China Halts Stem-Cell Trial Applications as Regulation Tightens

China will halt new applications for clinical trials of stem-cell products until July 1 as part of a year-long campaign to regulate the development of the industry, a Ministry of Health spokesman said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.